Viking Therapeutics, Inc. (VKTX) Stock Price & Analysis

Viking Therapeutics, Inc. (VKTX) rose 2.62% to USD 34.87 as of September 8, 2026 at 05:43 UTC, according to Nexqual real-time market data.

VKTX last closed at USD 34.87; the session ranged USD 33.56–34.95 on volume of 1,402,465 shares. Market capitalization is —, with a 52-week range of USD 22.96–43.15 (NCM). Source: Nexqual, September 8, 2026 at 05:43 UTC.

Key Statistics (as of September 8, 2026 at 05:43 UTC)

Technical Analysis (VKTX)

Nexqual's technical model rates VKTX "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:43 UTC.

From Viking Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)

Key Strengths & Strategy (as disclosed to the SEC)

• Reimbursement, Anti-Kickback and False Claims Laws and Other Regulatory Matters In the U.S., the research, manufacturing, distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare & Medicaid Services, or CMS, other divisions of the U.S.
• In addition, the first NDA or Biologics License Application, or BLA, applicant to receive orphan drug designation for a particular drug is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years in the United States, except in limited circumstances.
• Third party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development.
• If third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.

Partnerships

• To receive the six-month pediatric market exclusivity, we would need to receive a Written Request from the FDA, conduct the requested studies in accordance with a written agreement with the FDA or, if there is no written agreement, in accordance with commonly accepted scientific principles, and submit reports of the studies.
• Among the provisions of the ACA of greatest importance to the pharmaceutical industry are the following: • The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer's covered outpatient drugs furnished to Medicaid patients.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:43 UTC. This page is informational and not investment advice.